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Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic pathogen
that causes respiratory infection in humans, ranging from asymptomatic to severe pneumonia.
In dromedary camels, the virus only causes a mild infection but it spreads efficiently between
animals. Differences in the behavior of the virus observed between individuals, as well as between
humans and dromedary camels, highlight the role of host factors in MERS-CoV pathogenesis and
transmission. One of these host factors, the MERS-CoV receptor dipeptidyl peptidase-4 (DPP4),
may be a critical determinant because it is variably expressed in MERS-CoV-susceptible species as
well as in humans. This could partially explain inter- and intraspecies differences in the tropism,
pathogenesis, and transmissibility of MERS-CoV. In this review, we explore the role of DPP4 and
other host factors in MERS-CoV transmission and pathogenesis—such as sialic acids, host proteases,
and interferons. Further characterization of these host determinants may potentially offer novel
insights to develop intervention strategies to tackle ongoing outbreaks.
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1. Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel pathogen that was isolated
in late 2012 [1]. Since then, the virus has caused multiple outbreaks and infected more than 2000
individuals, [2] who then develop a respiratory infection ranging in severity from asymptomatic to
fatal [3,4]. Severe-to-fatal MERS-CoV patients have a higher chance of transmitting this virus since
they shed a higher amount of virus progeny in comparison to the asymptomatic-to-mild ones [5–8].
Identifying and quarantining these patients in healthcare facilities where outbreaks have occurred,
together with implementing proper infection control, has been effective in reducing transmission and
containing these outbreaks [9,10]. However, new MERS-CoV cases are still being reported, especially
in the Arabian Peninsula [2,11]. This is partly due to the continuous zoonotic introduction of this virus
to the human population in this region by dromedaries [12]. The dromedary camel is the only animal
species that has been reported to transmit this virus to humans [13–16]. MERS-CoV infection in these
animals merely causes mild upper respiratory tract infection [17,18], but seroepidemiological studies
showed that this virus has been circulating in dromedary camels for decades, suggesting the efficient
transmission of MERS-CoV in this species [19–22].
Although the clinical manifestations, as well as transmission, are remarkably different in
MERS-CoV-infected humans and dromedary camels, the viruses isolated from these two species
are highly similar, if not indistinguishable [12,16]. This indicates that host factors play a significant
role in MERS-CoV pathogenesis and transmission. However, the identity of these host factors and
how they affect the pathogenesis and transmission of MERS-CoV are generally not well understood.
Dipeptidyl peptidase-4 (DPP4)—the MERS-CoV receptor, sialic acids, proteases, and interferons are
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all examples of potentially critical host factors that have been shown to affect MERS-CoV infection
in vitro [23–26]. This review highlights the role of some MERS-CoV-interacting host factors—especially
DPP4—in MERS-CoV pathogenesis and transmission.
2. MERS-CoV-Interacting Host Factors
MERS-CoV infection of a target cell is initiated by the virus attachment to the cell surface [23,27].
MERS-CoV uses the N-terminal part of its spike (S)—the so called S1 protein (Figure 1A)—to
bind to two host cell surface molecules, dipeptidyl peptidase-4 (DPP4) and α2,3-sialic acids [23,24].
DPP4 is the functional receptor of MERS-CoV; its absence renders cells resistant to this virus,
while its transient expression in non-susceptible cells permits viral replication [23]. DPP4 is a serine
exopeptidase, which is either expressed at the cell surface or shed in a soluble form. It has the capacity
to cleave-off dipeptides from polypeptides with either L-proline or L-alanine at the penultimate
position. Accordingly, DPP4 is capable of cutting various substrates, such as hormones, cytokines,
chemokines, and neuropeptides, allowing it to be involved in multiple physiological functions
as well as pathophysiological conditions [28]. This enzymatic activity is mediated by the α/β
hydrolase domain of DPP4, while MERS-CoV infection is mediated by the binding of S1 protein
to the β-propeller domain of this exopeptidase (Figure 1B) [28–31]. There are 11 critical residues within
the β-propeller domain that directly interact with the S1 protein [29–31]. These residues are quite
conserved in camelids, primates, and rabbits—species shown to be susceptible to MERS-CoV [17,31–33].
In contrast, ferrets, rats, and mice resist MERS-CoV infection due to differences in some critical DPP4
residues [31,34–36]. These data illustrate that DPP4 has the capacity to determine the host range
of MERS-CoV.
Figure 1. Schematic figure depicting four structural proteins of Middle East respiratory syndrome
coronavirus (MERS-CoV), i.e., S, E, M, and N proteins (A); a cartoon representation of MERS-CoV
S1 protein binding to DPP4 (PDB code 4L72) (B). The S protein consists of the S1 and S2 subunits.
The α/β hydrolase domain of DPP4 is indicated in red, β-propeller domain in green, while part of the
MERS-CoV S1 protein is shown in blue.
Other MERS-CoV-interacting host factors besides DPP4 are less extensively studied and have
mostly been investigated in vitro. Glycotopes of α2,3-sialic acids coupled with 5-N-acetylated
neuraminic acid are recognized by the S1 protein of MERS-CoV during attachment [24]. In the
absence of these glycotopes, MERS-CoV entry is reduced but not abolished, indicating their function as
an attachment factor rather than a receptor [24]. Besides α2,3-sialic acids, CEACAM5 and GRP78 have
also been suggested to be attachment factors for MERS-CoV, but their roles in vivo during MERS-CoV
infection are not clear at this moment [37,38]. Post attachment, MERS-CoV uses the C-terminal part
of its S protein—known as S2 (Figure 1A)—to interact with host proteases, such as furin, TMPRSS2,
and cathepsins [39–42]. These proteases cleave the S protein and induce conformational changes,
allowing fusion between viral and host cellular membranes, resulting in the release of viral RNA
into the cell cytoplasm [27]. TMPRSS2 and DPP4 are held in one complex at the cell surface by
a scaffolding protein, the tetraspanin CD9, leading to a rapid and efficient entry of MERS-CoV into the
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susceptible cells [43]. Once fusion with host cell membranes has occurred, MERS-CoV subsequently
replicates its genetic material and produces viral proteins in the cell cytoplasm to generate new virus
progeny. During this stage, MERS-CoV uses its nsp3–4 polyproteins to build its replication organelles
as well as its accessory proteins such as the 4a and 4b proteins to inhibit host anti-viral defense
mechanisms [44–54]. However, the capacity of MERS-CoV accessory proteins to impede several
pathways of host immune response in the lungs may be limited. MERS-CoV inoculation of macaques
and genetically modified mice generally results in limited clinical manifestations; thus, adapting this
virus through serial passaging or defecting the type I interferon pathway may be needed to enhance
viral replication and pathogenesis in these animals [32,55–58]. These observations, together with
studies showing type I interferon capacity to inhibit MERS-CoV infection in vitro [25,59], highlight
the importance of the innate immune response, especially type I interferon, as an inhibiting factor
for MERS-CoV.
3. Host Factors in MERS-CoV Transmission
So far MERS-CoV has been isolated from dromedary camels and humans [1,60]. Both species are
not only susceptible to MERS-CoV infection, but also capable of transmitting this virus [7,12–18,22].
However, current data indicate that virus spread is more efficient in dromedary camels than in
humans [5,7,19–21,61]. This difference in transmissibility could be partially due to the different tropism
of MERS-CoV in these two species. In dromedaries, MERS-CoV has been shown to replicate in the nasal
epithelium upon experimental in vivo infection [17], while in humans, MERS-CoV mainly replicates
in the lower respiratory tract, particularly in the bronchiolar and alveolar epithelia [23,62–65]. Higher
viral RNA levels in the sputum and lavage samples of MERS-CoV patients compared to nasal and throat
swabs are consistent with the tropism of MERS-CoV in humans [66–68]. This different MERS-CoV
tropism in dromedary camels and humans is in line with the localization of DPP4 in the respiratory
tract tissues of these two species. In humans, DPP4 is absent in the nasal epithelium but present in
the lower respiratory tract epithelium, mainly in type II pneumocytes [69,70]. In contrast, DPP4 is
expressed in the nasal epithelium of dromedary camels [69]. This difference in DPP4 localization
between humans and dromedary camels therefore explains MERS-CoV tropism in these two species
and highlights DPP4 as an essential determinant of MERS-CoV tropism.
DPP4 localization has also been investigated in many other MERS-CoV-susceptible species.
In Gambian and Egyptian fruit bats, DPP4 is expressed in the respiratory tract and intestinal epithelium,
suggesting that MERS-CoV can target both tissues [71]. In line with this finding, MERS-CoV inoculation
via intranasal and intraperitoneal routes in the Jamaican fruit bat led to viral RNA shedding both in
the respiratory tract and the intestinal tract [72]. In contrast to frugivorous bats, DPP4 is limitedly
expressed in the respiratory tract epithelium of two insectivorous bats, i.e., common pipistrelle and
common serotine bats, but abundant in their intestinal epithelium [71]. Accordingly, sequences
of MERS-like-CoVs were mainly obtained from rectal swabs and fecal samples of insectivorous
bats [73–80]. These findings not only support insectivorous bats as the origin host of MERS-CoV [73–80],
but also indicate the importance of intestinal tropism and fecal–oral transmission of MERS-like-CoV in
these insectivorous bats.
Besides bats, humans, and dromedary camels, other animal species have also been proposed
as potential hosts of MERS-CoV. Remarkably, DPP4 of horses, llamas, alpacas, pigs, bovines, goats,
sheep, and rabbits has been demonstrated to recognize the S protein of MERS-CoV [81,82]. In most
of these species, there is a preferential upper respiratory tract expression of DPP4 observed. Rabbits
express DPP4 in the upper and lower respiratory tract epithelium, and thus may allow MERS-CoV to
replicate in both compartments [33,83]. Horses, llamas, and pigs mainly express DPP4 in the upper
respiratory tract—particularly the nasal epithelium [84]. Upon intranasal MERS-CoV inoculation,
llamas, alpacas, and pigs developed upper respiratory tract infection, while horses did not seroconvert
and only shed infectious virus in a limited amount [84–88]. The reason why horses seem to be
less permissive to MERS-CoV remains to be investigated, but a chronic co-infection in the guttural
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pouch, a common disease among horses, might be one of the explanations. This guttural pouch
infection results in excessive mucus production that might hinder MERS-CoV from attaching and
entering the nasal epithelium [84,89,90]. Sheep, on the other hand, did not seem to express significant
levels of DPP4 in their respiratory tract, and thus did not seroconvert nor shed infectious virus upon
experimental MERS-CoV inoculation [84,88]. Comparable to sheep, goats limitedly shed infectious
virus upon experimental infection and did not transmit this virus to other naïve goats upon direct
contact [88]. The results of experimental MERS-CoV infection in livestock animals are in line with
data from epidemiological studies. MERS-CoV seropositive llamas and alpacas are present in the field,
while horses, goats, and sheep are generally found to be seronegative [22,86,87,91–98].
Given the fact that experimental in vivo infection studies and DPP4 expression analysis in different
animal species revealed that dromedary camels are not the only animals in which MERS-CoV has
an upper respiratory tract tropism [17,18,83,84], it is then relevant to question whether other animals
can potentially spread MERS-CoV as well. New World camelids, i.e., alpacas and llamas, are able to
transmit the virus to respective naïve animals upon contact [86]. Pigs and rabbits, on the other hand,
hardly transmit the virus—neither by contact nor airborne routes [83,99]. Most likely, this is caused
by the fact that pigs and rabbits, unlike dromedary camels, shed low levels of infectious virus upon
MERS-CoV inoculation (Figure 2). This difference indicates that other host factors besides DPP4 could
cause interspecies variation in MERS-CoV infection. Indeed, several glycotopes of α2,3-sialic acids
that function as attachment factors of MERS-CoV are present in the nasal epithelium of dromedary
camels but absent in that of rabbits and pigs (Figure 3) [24,100]. The lack of these glycotopes in pigs
and rabbits might limit the susceptibility and transmission of MERS-CoV in these animals. Although
the role of these glycotopes in MERS-CoV transmission still requires further investigation, it remains
plausible that an efficient transmission of this virus might require the presence of both DPP4 and
MERS-CoV-recognized glycotopes of α2,3-sialic acids (Figure 3).
Figure 2. Schematic overview of viral RNA and infectious virus shedding of MERS-CoV-inoculated
dromedary camels, pigs, and rabbits. Each data point represents the average data from previous
experiments [17,33,84]. Viral RNA is measured in TCID50/mL genome equivalents, while infectious
virus is expressed in TCID50/mL.
Besides entry and attachment receptors, MERS-CoV has been demonstrated to use both cell
surface and lysosomal proteases to enter its target cells [39,40,43,101]. The preference of MERS-CoV
to use certain host proteases is influenced by the type of target cell and the cleavage stage of their S
protein prior to infection [40]. It has also been reported that the lysosomal proteases from bat cells
support coronavirus spike-mediated virus entry more efficiently than their counterparts from human
cells [39]. These observations suggest that host proteases from different host species may determine
the species and tissue tropism of MERS-CoV.
Because MERS-CoV has been circulating in dromedary camels for decades before emerging in the
human population [19–22], it is plausible that this virus inhibits the immune response of dromedary
camels more efficiently than that of other species, including pigs and rabbits. The difference in immune
response among MERS-CoV-susceptible species is therefore another factor that might yield interspecies
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variation in permissiveness to MERS-CoV. Characterizing the difference in host proteases and immune
responses among MERS-CoV-susceptible species, as performed for DPP4 and MERS-CoV-recognized
α2,3-sialic acid glycotopes (Figure 3), has not yet been investigated. These data, however, may further
explain interspecies variation in MERS-CoV infection and transmission.
Figure 3. Schematic representation of DPP4 expression and MERS-CoV-recognized α2,3-sialic acid
glycotopes in the respiratory tract of dromedary camel, pig, rabbit, human, and sheep.
4. Host Factors in MERS-CoV Pathogenesis
MERS-CoV causes respiratory infection in humans ranging from asymptomatic to severe
pneumonia [3,4]. However, it is currently unclear what causes this intraspecies variation. Epidemiology
data indicate that individuals with certain risk factors are at higher risk of developing severe MERS-CoV
infection [4,102]. This implies that some host factors may dictate the outcome of MERS-CoV infection,
thus rendering intraspecies variation. Two of the risk factors, i.e., smoking and chronic obstructive
pulmonary disease (COPD), have been shown to upregulate DPP4 expression in the lungs [70,102–104],
suggesting DPP4 as a possible reason for intraspecies variation observed among MERS-CoV patients.
In healthy human lungs, DPP4 is almost exclusively expressed in type II pneumocytes [69,70].
Type II pneumocytes are small cuboidal cells that can regenerate alveolar epithelium upon injury,
and roughly cover 2% of the alveolar surface area. Meanwhile, around 95% of the surface area of
the alveolus is occupied by type I pneumocytes that are morphologically flat and responsible for
gas exchange [105,106]. In the lungs of smokers and COPD patients, unlike in healthy human lungs,
DPP4 is prominently expressed in both type I and II pneumocytes, indicating upregulated expression
on type I pneumocytes [104]. Autopsy reports from fatal MERS-CoV patients showed that both
type I and II pneumocytes expressed DPP4 and became infected by MERS-CoV, proposing a role of
DPP4-expressing type I pneumocytes in MERS-CoV pathogenesis [64,107]. Damage to type I cells
in the lung alveoli during viral infection may lead to diffuse alveolar damage [108]. In line with
observations made in human MERS cases, common marmosets that express DPP4 in both type I and
II pneumocytes have been reported to produce more infectious virus upon experimental MERS-CoV
infection, compared to rhesus and cynomolgus macaques that merely expressed DPP4 in type II
pneumocytes [58,109–112]. Accordingly, these common marmosets developed moderate-to-severe
infection, while macaques generally developed mild transient pneumonia [32,58,109–112]. Similarly,
in genetically modified mice that displayed MERS-CoV tropism for type II pneumocytes, only mild
clinical manifestations were observed upon MERS-CoV infection [56,113]. Adapting MERS-CoV
through serial passaging or upregulating DPP4 expression throughout the airway epithelium in
mice, however, will induce severe clinical disease [55,56]. These data altogether support the role of
DPP4-expressing type I pneumocytes in the pathogenesis of severe MERS-CoV infection.
The differential expression of host factors that limits the infection should also be taken into
account. DPP4 in soluble form has been demonstrated to protect against MERS-CoV infection
in vitro and in a mouse model [23,114]; however, its presence in the lungs and role in MERS-CoV
pathogenesis remain to be investigated. The host immune response also has the capacity to inhibit
MERS-CoV infection. MERS-CoV has been shown to replicate to higher levels in immunocompromised
rhesus macaques [115], consistent with the observation that immunocompromised individuals have
difficulties clearing MERS-CoV upon infection [68,107,116]. The survivors of MERS-CoV infection have
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been shown to develop virus-specific CD4+ and CD8+ T cell responses, implying the role of T cells in
virus clearance [117]. However, the depletion of T cells in mice can either lead to failure in MERS-CoV
clearance or improvement in clinical outcome, depending on the type of mouse model used [57,118].
Therefore, the role of adaptive immune response in MERS-CoV pathogenesis is currently unclear.
On the other hand, one of the main components of the host innate immune response, type I interferon,
inhibits MERS-CoV replication in susceptible cells, partly by inhibiting double membrane vesicles
(DMV) formation [25,57,59,119,120]. The absence of type I interferon signaling in mice also resulted
in more severe clinical manifestations and histopathological lesions upon MERS-CoV infection [57].
Advance age, which can cause delayed type I interferon response upon viral infection, is a well-known
risk factor for fatal MERS-CoV infection [4,102,121–123]. Collectively, these data highlight the role of
host innate immune response as a potent inhibitor for MERS-CoV infection.
It is indubitable that severe MERS-CoV infection is not solely driven by the pathogen.
Additional underlying conditions increase MERS-CoV replication and induce severe-to-fatal clinical
manifestations [4,11,103,124,125]. It is plausible that more than one underlying condition is needed
to yield a fatal outcome. DPP4 upregulation in type I pneumocytes and insufficient type I interferon
response might be crucial determinants for severe MERS-CoV infection (Figure 4). Further investigation
of the host determinants of MERS-CoV pathogenesis may offer insights for developing novel
therapeutic measures.
Figure 4. MERS-CoV infection in the lungs of asymptomatic-to-mild (left panel) and severe-to-fatal
cases (right panel). Shown is a hypothetical model with two critical host determinants, DPP4 and
interferon, differentially expressed in asymptomatic-to-mild and severe-to-fatal MERS-CoV infection.
5. Concluding Remarks and Future Perspectives
Although MERS-CoV has been reported to undergo some genotypic changes since it emerged in
the human population [12,126–129], this has not resulted in distinct phenotypic changes so far [63,126].
Therefore, host factors remain the most significant determinant in explaining inter- and intraspecies
variations observed in MERS-CoV pathogenesis and transmission. DPP4 and MERS-CoV-recognized
α2,3-sialic acids might partially explain these variations, since their localization has been demonstrated
to be variable between MERS-CoV-susceptible species [69,71,84,100]. DPP4 expression in human lungs
has also been shown to vary due to certain comorbidities [70,96,104]. Nevertheless, it is undoubtable
that the inter- and intraspecies variation in MERS-CoV pathogenesis and transmission is a complex
phenomenon influenced by more than one host factor. Current data suggest proteases and interferons as
other critical host factors, but how they instigate inter- and intraspecies variations, as well as their role
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in MERS-CoV pathogenesis and transmission, still remain to be further elucidated. Characterization of
the host determinants of MERS-CoV pathogenesis and transmission could potentially offer insight into
this virus epidemiology and guide novel therapeutic development. It may also help to identify the most
vulnerable individuals to protect against MERS-CoV infection—for example, by using vaccination.
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